Essential Partners
CRSP icon

Essential Partners’s CRISPR Therapeutics CRSP Stock Holding History

Essential Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$332 Hold
6
– – ﹤0.01% 2497
2026
Q2 		$327 Sell
6
-65
-92% -$3.43K ﹤0.01% 2553
2026
Q1 		$3.38K Hold
71
– – ﹤0.01% 1764
2025
Q4 		$3.72K Sell
71
-1
-1% -$60 ﹤0.01% 1547
2025
Q3 		$4.67K Buy
72
+1
+1% +$57 ﹤0.01% 1452
2025
Q2 		$3.45K Buy
+71
New +$2.75K ﹤0.01% 1155

Other funds holding CRSP

Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
Slow Capital
Slow Capital Greenbrae, California $890M AUM 40.96% 1-Year Est. Return
NTV Asset Management
NTV Asset Management Charleston, West Virginia $1.08B AUM 23.94% 1-Year Est. Return
Green Alpha Advisors
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return
Canal Insurance Company
Canal Insurance Company Greenville, South Carolina $426M AUM 30.47% 1-Year Est. Return
Bouvel Investment Partners
Bouvel Investment Partners Phoenixville, Pennsylvania $433M AUM 51.2% 1-Year Est. Return

Essential Partners's CRSP Position: Q3 2026 in Review

Essential Partners held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 6 shares worth $332. The position accounts for ﹤0.01% of the portfolio, ranked #2497.

Essential Partners first reported a position in CRSP in Q2 2025 and has held it in 6 quarters since. The position peaked at $4.67K in Q3 2025. 88 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Essential Partners held 6 shares of CRISPR Therapeutics worth $332 as of Q3 2026.
  • Essential Partners left its CRISPR Therapeutics share count unchanged in Q3 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2497 holding.
  • Essential Partners first reported a position in CRISPR Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Essential Partners's CRISPR Therapeutics position peaked at $4.67K in Q3 2025.
  • 88 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.